Home › Compare › TNTRQ vs ABBV
TNTRQ yields 4000000.00% · ABBV yields 3.06%● Live data
📍 TNTRQ pulled ahead of the other in Year 1
Combined, TNTRQ + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TNTRQ + ABBV for your $10,000?
Tintri, Inc. develops and markets an enterprise cloud platform combining cloud management software technology and a range of all-flash storage systems for virtualized and cloud environments in the United States and internationally. The company's platform provides large organizations and cloud service providers with public cloud capabilities inside their data centers and public cloud services. Its products and technologies include Tintri CONNECT, a proprietary software architecture for virtualized and cloud applications; Tintri OS, which helps the interaction between the virtualized infrastructure and the underlying storage serving that infrastructure; Tintri Global Center, an intelligent data and system management product; and VM Scale-out software, which creates resource pools of Tintri storage systems and optimizes the location of applications. The company's products and technologies also include predictive analytics solutions for customers to model their current and future storage requirements; ReplicateVM, the replication solutions for data protection and disaster recovery; SyncVM, a solution for copy data management; SecureVM, a solution for encryption of data-at-rest; Tintri Cloud Connector, which allows customers to use public cloud storage for storing snapshots; and storage systems, such as EC6000 all-flash systems, T800 hybrid-flash systems, and T1000 all-flash system. It also offers its products related support, installation, and training services. The company serves customer in education, financial services, insurance, healthcare, manufacturing, and automotive technology, as well as cloud service providers. Tintri, Inc. was founded in 2008 and is headquartered in Mountain View, California. On July 10, 2018, Tintri, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on October 8, 2019.
Full TNTRQ Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.